| 1 |
Golledge J, Muller J, Daugherty A, et al. Abdominal aortic aneurysm: pathogenesis and implications for management[J]. Arterioscler Thromb Vasc Biol, 2006,26(12):2605-2613.
|
| 2 |
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015,385(9963):117-171.
|
| 3 |
Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery[J]. Eur J Vasc Endovasc Surg, 2011,41Suppl 1:S1-S58.
|
| 4 |
Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm[J]. J Vasc Surg, 2018,67(1):2-77.
|
| 5 |
Sweeting MJ, Patel R, Powell JT, et al. Endovascular repair of abdominal aortic aneurysm in patients physically ineligible for open repair: very long-term follow-up in the EVAR-2 randomized controlled trial[J]. Ann Surg, 2017,266(5):713-719.
|
| 6 |
Cao P, De Rango P, Verzini F, et al. Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial[J]. Eur J Vasc Endovasc Surg, 2011,41(1):13-25.
|
| 7 |
Buck DB, van Herwaarden JA, Schermerhorn ML, et al. Endovascular treatment of abdominal aortic aneurysms[J]. Nat Rev Cardiol, 2014,11(2):112-123.
|
| 8 |
Golledge J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments[J]. Nat Rev Cardiol, 2019,16(4):225-242.
|
| 9 |
Salata K, Syed M, Hussain MA, et al. Renin-angiotensin system blockade does not attenuate abdominal aortic aneurysm growth, rupture rate, or perioperative mortality after elective repair[J]. J Vasc Surg, 2018,67(2):629-636.e2.
|
| 10 |
Golledge J, Singh TP. Effect of blood pressure lowering drugs and antibiotics on abdominal aortic aneurysm growth: a systematic review and meta-analysis[J]. Heart, 2021,107(18):1465-1471.
|
| 11 |
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations[J]. Ann Intern Med, 2015,162(11):777-784.
|
| 12 |
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ, 2011,343:d5928.
|
| 13 |
Shim SR, Kim SJ, Lee J, et al. Network meta-analysis: application and practice using R software[J]. Epidemiol Health, 2019,41:e2019013.
|
| 14 |
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial[J]. J Clin Epidemiol, 2011,64(2):163-171.
|
| 15 |
Veroniki AA, Vasiliadis HS, Higgins JP, et al. Evaluation of inconsistency in networks of interventions[J]. Int J Epidemiol, 2013,42(1):332-345.
|
| 16 |
Bowes J, Budu-Aggrey A, Huffmeier U, et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis[J]. Nat Commun, 2015,6:6046.
|
| 17 |
Burry L, Hutton B, Williamson DR, et al. Pharmacological interventions for the treatment of delirium in critically ill adults[J]. Cochrane Database Syst Rev, 2019,9(9):CD011749.
|
| 18 |
Baxter BT, Matsumura J, Curci JA, et al. Effect of doxycycline on aneurysm growth among patients with small infrarenal abdominal aortic aneurysms: a randomized clinical trial[J]. JAMA, 2020,323(20):2029-2038.
|
| 19 |
Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study[J]. J Vasc Surg, 2001,34(4):606-610.
|
| 20 |
Meijer CA, Stijnen T, Wasser MN, et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial[J]. Ann Intern Med, 2013,159(12):815-823.
|
| 21 |
Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion[J]. Br J Surg, 2001,88(8):1066-1072.
|
| 22 |
Karlsson L, Gnarpe J, Bergqvist D, et al. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial[J]. J Vasc Surg, 2009,50(1):23-29.
|
| 23 |
Sillesen H, Eldrup N, Hultgren R, et al. Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm[J]. Br J Surg, 2015,102(8):894-901.
|
| 24 |
Lindholt JS, Henneberg EW, Juul S, et al. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms[J]. Int Angiol, 1999,18(1):52-57.
|
| 25 |
Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial[J]. J Vasc Surg, 2002,35(1):72-79.
|
| 26 |
Golledge J, Pinchbeck J, Tomee SM, et al. Efficacy of telmisartan to slow growth of small abdominal aortic aneurysms: a randomized clinical trial[J]. JAMA Cardiol, 2020,5(12):1374-1381.
|
| 27 |
Bicknell CD, Kiru G, Falaschetti E, et al. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK)[J]. Eur Heart J, 2016,37(42):3213-3221.
|
| 28 |
Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms[J]. Eur J Vasc Endovasc Surg, 2006,31(5):453-463.
|
| 29 |
Sterpetti AV. Doxycycline and growth of abdominal aortic aneurysms[J]. JAMA, 2020,324(15):1568-1569.
|
| 30 |
Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection[J]. J Am Coll Cardiol, 2018,72(12):1369-1378.
|
| 31 |
Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study[J]. BMJ, 2018,360:k678.
|
| 32 |
Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study[J]. BMJ Open, 2015,5(11):e010077.
|
| 33 |
Lee CC, Lee MT, Chen YS, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone[J]. JAMA Intern Med, 2015,175(11):1839-1847.
|
| 34 |
Newton ER, Akerman AW, Strassle PD, et al. Association of fluoroquinolone use with short-term risk of development of aortic aneurysm[J]. JAMA Surg, 2021,156(3):264-272.
|
| 35 |
Lawaetz Kristensen K, Hallas J, Sanddal Lindholt J. Fluoroquinolones as a trigger for rupture of abdominal aortic aneurysm: A case-crossover analysis[J]. Basic Clin Pharmacol Toxicol, 2021,129(1):44-51.
|
| 36 |
Dong YH, Chang CH, Wang JL, et al. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection[J]. JAMA Intern Med, 2020, 180(12):1587-1595.
|
| 37 |
Leach SD, Toole AL, Stern H, et al. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms[J]. Arch Surg, 1988,123(5):606-609.
|
| 38 |
Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade[J]. J Vasc Surg, 1994,19(4):727-731.
|
| 39 |
Malekzadeh S, Fraga-Silva RA, Trachet B, et al. Role of the renin-angiotensin system on abdominal aortic aneurysms[J]. Eur J Clin Invest, 2013,43(12):1328-1338.
|
| 40 |
Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study[J]. Lancet, 2006,368(9536):659-665.
|
| 41 |
Wemmelund H, Høgh A, Hundborg HH, et al. Preadmission use of renin-angiotensin blockers and rupture of abdominal aortic aneurysm: a nationwide, population-based study[J]. Pharmacoepidemiol Drug Saf, 2016,25(2):141-150.
|
| 42 |
Elbadawi A, Omer M, Ogunbayo G, et al. Antiplatelet medications protect against aortic dissection and rupture in patients with abdominal aortic aneurysms[J]. J Am Coll Cardiol, 2020,75(13):1609-1610.
|
| 43 |
Lindholt JS, Sorensen HT, Michel JB, et al. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms[J]. Vasc Endovascular Surg, 2008,42(4):329-334.
|
| 44 |
Wanhainen A, Mani K, Kullberg J, et al. The effect of ticagrelor on growth of small abdominal aortic aneurysms-a randomized controlled trial[J]. Cardiovasc Res, 2020,116(2):450-456.
|
| 45 |
Aoki A, Suezawa T, Sangawa K, et al. Effect of type II endoleaks and antiplatelet therapy on abdominal aortic aneurysm shrinkage after endovascular repair[J]. J Vasc Surg, 2011,54(4):947-951.
|
| 46 |
Raffort J, Lareyre F, Clément M, et al. Diabetes and aortic aneurysm: current state of the art[J]. Cardiovasc Res, 2018,114(13):1702-1713.
|
| 47 |
Sweeting MJ, Thompson SG, Brown LC, et al. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms[J]. Br J Surg, 2012,99(5):655-665.
|
| 48 |
Dattani N, Sayers RD, Bown MJ. Diabetes mellitus and abdominal aortic aneurysms: a review of the mechanisms underlying the negative relationship[J]. Diab Vasc Dis Res, 2018,15(5):367-374.
|
| 49 |
Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions[J]. Eur Heart J, 2008,29(5):665-672.
|
| 50 |
Morris D, Sherliker P, Clack R, et al. The association of blood glucose and diabetes with peripheral arterial disease involving different vascular territories: results from 628 246 people who attended vascular screening[J]. Eur Heart J, 2017, 38(suppl_1): ehx504.
|
| 51 |
Vasamsetti SB, Karnewar S, Kanugula AK, et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis[J]. Diabetes, 2015,64(6):2028-2041.
|
| 52 |
Wanhainen A, Unosson J, Mani K, et al. The metformin for abdominal aortic aneurysm growth inhibition (MAAAGI) trial[J]. Eur J Vasc Endovasc Surg, 2021,61(4):710-711.
|
| 53 |
Golledge J, Moxon J, Pinchbeck J, et al. Association between metformin prescription and growth rates of abdominal aortic aneurysms[J]. Br J Surg, 2017,104(11):1486-1493.
|
| 54 |
O'Donnell TF, Deery SE, Shean KE, et al. Statin therapy is associated with higher long-term but not perioperative survival after abdominal aortic aneurysm repair[J]. J Vasc Surg, 2018, 68(2):392-399.
|
| 55 |
Alshaikh HN, Bohsali F, Gani F, et al. Statin intensity and postoperative mortality following open repair of intact abdominal aortic aneurysm[J]. BJS Open, 2018,2(6):411-418.
|
| 56 |
Karrowni W, Dughman S, Hajj GP, et al. Statin therapy reduces growth of abdominal aortic aneurysms[J]. J Investig Med, 2011,59(8):1239-1243.
|
| 57 |
Mathisen SR, Abdelnoor M. Beneficial effect of statins on total mortality in abdominal aortic aneurysm (AAA) repair[J]. Vasc Med, 2017,22(5):406-410.
|
| 58 |
Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery[J]. Am J Med, 2004,116(2):96-103.
|
| 59 |
Pinchbeck JL, Moxon JV, Rowbotham SE, et al. Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate therapy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME -2 Trial[J]. J Am Heart Assoc, 2018, 7(19): e009866.
|
| 60 |
Moxon JV, Rowbotham SE, Pinchbeck JL, et al. A randomised controlled trial assessing the effects of peri-operative fenofibrate administration on abdominal aortic aneurysm pathology: outcomes from the FAME trial[J]. Eur J Vasc Endovasc Surg, 2020,60(3):452-460.
|